@article{642032d0f4794c999c7277d8e275fbcf,
title = "Evaluation of Antibody Responses to COVID-19 Vaccines among Solid Tumor and Hematologic Patients",
abstract = "Vaccination is the primary public health strategy to cope with the COVID-19 pandemic. Although solid tumor and hematologic patients are at higher risk of serious COVID-19-related complications, data on immune responses to COVID-19 vaccines in this patient cohort are particularly scarce. The present study, therefore, aimed at the standardized determination of anti-SARS-CoV-2 spike protein antibody titers among non-vaccinated versus vaccinated solid tumor and hematologic patients who are under clinical observation or under treatment at the University Hospital Krems. Standardized anti-SARS-CoV-2 S antibody titers of a total of 441 patients were retrospectively analyzed. Our results show that antibody titers against the SARS-CoV-2 spike protein are significantly higher in solid tumor versus hematologic patients. While SARS-CoV-2 antibody titers were equal among sexes, an age-dependent decrease was observed. Of note, our studies additionally show that complete vaccination represents a valuable predictor for high anti-SARS-CoV-2 antibody responses in solid tumor and hematologic patients. In summary, to date, this is one of the largest studies to comprehensively evaluate the impact of various COVID-19 vaccines on anti-SARS-CoV-2 S antibody production in solid tumor and hematologic patients. Our findings aim to support future vaccination strategies in these highly vulnerable patients, including vaccination booster programs and alternative protective approaches.",
keywords = "Antibody response, COVID-19, Cancer patients, SARS-CoV-2, SARS-CoV-2 S vaccine",
author = "Josef Singer and Nguyen-Son Le and Daniel Mattes and Valerie Klamminger and Klaus Hackner and Nicole Kolinsky and Michaela Scherb and Peter Errhalt and Gudrun Kreye and Martin Pecherstorfer and Sonia Vallet and Klaus Podar",
note = "Funding Information: Conflicts of Interest: J.S. declares honorarium payments from Abbvie, Amgen, Gilead, Janssen, Merck, Merck Sharp & Dohme, Novartis, Pfizer, Roche and Servier as an invited speaker or expert consulting on other topics than SARS-CoV-2 and vaccination. K.H. declares honorarium from Amgen, Boehringer Ingelheim and Roche as an expert consulting on other topics than SARS-CoV-2 and vaccination. M.P. declares financial support from Roche for research projects other than SARS-CoV-2 and vaccination. S.V. received speaker{\textquoteright}s honoraria from Bristol Myers Squibb, MSD, Pfizer and consultancy fees from Roche, Eusa, MSD and Merck on other topics than SARS-CoV-2 and vaccination. K.P. has received speaker{\textquoteright}s honoraria from Celgene, Amgen Inc. and Janssen Pharmaceuticals, consultancy fees from Celgene, Takeda and Janssen Pharmaceuticals and research support from Roche Pharmaceuticals on other topics than SARS-CoV-2 and vaccination. All other authors have no conflict of interest with regard to this work. Funding Information: Funding: This investigation was supported by the WST3-F-5031 298/003-2019 (KP). The authors want to appreciate the contribution of N{\"O} Landesgesundheitsagentur, the legal entity of University Hospitals in Lower Austria, for providing the organizational framework to conduct this research. They also would like to acknowledge support by Open Access Publishing Fund of Karl Landsteiner University of Health Sciences, Krems, Austria. Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",
year = "2021",
month = aug,
day = "26",
doi = "10.3390/cancers13174312",
language = "English",
volume = "13",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "17",
}